Current state and potential applications of neonatal Fc receptor (FcRn) inhibitors in hematologic conditions
Authors:
- Jeremy W. JacobsJJJeremy W. Jacobs
- Garrett S. BoothGBGarrett S. Booth
- Ross M. FasanoRFRoss M. Fasano
- Eleni GavriilakiEleni Gavriilaki
- Elizabeth A. AbelsEAElizabeth A. Abels
- Thomas C. BinnsTBThomas C. Binns
- Zoe K. McQuiltenZMZoe K. McQuilten
- María Eva Mingot‐CastellanoMMMaría Eva Mingot‐Castellano
- Bipin N. SavaniBSBipin N. Savani
Open Access
- 26 September 2024
- journal article
- review article
- Published by Wiley in American Journal of Hematology
- Vol. 99 (12) , 2351-2366
Abstract
The neonatal fragment crystallizable (Fc) receptor (FcRn) transports IgG across mucosal surfaces and the placenta and protects IgG from degradation. Numerous clinical trials are investigating therapeutic FcRn inhibition for various immune‐mediated neuromuscular and rheumatologic conditions; however, FcRn inhibition also represents a potential therapy for IgG‐mediated hematologic conditions (e.g., immune thrombocytopenia, autoimmune hemolytic anemia, immune thrombotic thrombocytopenic purpura, acquired hemophilia, red blood cell/platelet alloimmunization). Current evidence derived from both in vitro and in vivo studies suggests that FcRn inhibitors effectively reduce total IgG levels without impacting its production or altering the levels of other immunoglobulin isotypes. Moreover, the risk of serious adverse events, including serious infections, appears to be lower than that seen with other commonly used immunomodulatory/immunosuppressive therapies, albeit in the setting of limited clinical trial data. Ultimately, additional clinical trials that include varied patient populations are required prior to incorporating these agents into standard treatment algorithms for most hematologic conditions. However, based on the pathophysiology of IgG‐mediated hematologic disorders and the mechanism of action of FcRn inhibitors, these agents may represent a future novel therapeutic strategy for patients with hematologic conditions caused by IgG antibodies.Keywords
This publication has 84 references indexed in Scilit:
- 2025 update on clinical trials in immune thrombocytopeniaAmerican Journal of Hematology, 2024
- How the United States syphilis epidemic may portend a resurgence of an unusual hematologic condition: The connection between syphilis and paroxysmal cold hemoglobinuriaAmerican Journal of Hematology, 2023
- Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special IssueJournal of Clinical Apheresis, 2023
- Therapeutic plasma exchange practices in immune thrombocytopenia related hospitalizations: Results from a nationally representative sampleJournal of Clinical Apheresis, 2022
- Coagulation factor inhibitors in COVID‐19: From SARS‐CoV‐2 vaccination to infectionResearch and Practice in Thrombosis and Haemostasis, 2022
- Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopeniaAmerican Journal of Hematology, 2019
- Incidence and predictive score for delayed hemolytic transfusion reaction in adult patients with sickle cell diseaseAmerican Journal of Hematology, 2017
- Pharmacokinetics of Monoclonal AntibodiesCPT: Pharmacometrics & Systems Pharmacology, 2017
- The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double‐blind, placebo‐controlled, dose‐ranging trialArthritis & Rheumatism, 2006
- Isolation and characterization of an Fc receptor from neonatal rat small intestineEuropean Journal of Immunology, 1985